2016 was an important year for CollPlant as it completed a clinical study and received its CE approval for VergenixSTR, entered into an exclusive distribution agreement with Arthrex to commercialise VergenixSTR in EMEA and launched VergenixFG in Europe. We expect CollPlant to build on this progress in 2017 by increasing its distribution of VergenixFG and orders from Arthrex, alongside developing its earlier-stage rhCollagen technology BioInk for 3D printing of organs and tissues. We note that there is a fund raising requirement this year. We have slightly increased our rNPV to $66m (NIS244m) on FY16 results having also rolled the model forward.
Written by
CollPlant Holdings |
Good progress in 2016 |
FY16 results |
Pharma & biotech |
4 April 2017 |
Share price performance
Business description
Next events
Analyst
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
2016 was an important year for CollPlant as it completed a clinical study and received its CE approval for VergenixSTR, entered into an exclusive distribution agreement with Arthrex to commercialise VergenixSTR in EMEA and launched VergenixFG in Europe. We expect CollPlant to build on this progress in 2017 by increasing its distribution of VergenixFG and orders from Arthrex, alongside developing its earlier-stage rhCollagen technology BioInk for 3D printing of organs and tissues. We note that there is a fund raising requirement this year. We have slightly increased our rNPV to $66m (NIS244m) on FY16 results having also rolled the model forward.
Year end |
Revenue (NISm) |
PBT* (NISm) |
EPS* (NIS) |
DPS (NIS) |
P/E (x) |
Yield (%) |
12/15 |
0.0 |
(18.7) |
(22.03) |
0.0 |
N/A |
N/A |
12/16 |
0.3 |
(27.9) |
(27.72) |
0.0 |
N/A |
N/A |
12/17e |
1.3 |
(16.3) |
(12.72) |
0.0 |
N/A |
N/A |
12/18e |
2.9 |
(17.8) |
(13.86) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
2016: A year of progress
CollPlant made good progress in 2016 with its tendinopathy product, VergenixSTR, completing a clinical study, receiving its CE approval and entering into an exclusive distribution agreement with Arthrex to commercialise in EMEA. It also treated its first VergenixFG commercial patients in Europe. CollPlant has a versatile technology, rhCollagen, with potentially broad clinical application and which according to the company offers a number of advantages. For a detailed overview see our recent initiation note here.
A strong 2017 possible if required funds raised
CollPlant recently announced that it had signed additional distribution agreements in Europe (Turkey and Switzerland) for its VergenixFG product (treatment for chronic and acute wounds). Together with the agreement with Arthrex, the announcement demonstrates that CollPlant is starting to deliver on its strategy for both VergenixFG and VergenixSTR respectively to gain traction in Europe and build end-user experience and clinical data. We continue to expect CollPlant to consider a launch in the US (via a partner/distributor) in c 24 months, depending on the rate of commercialisation.
Valuation: Increased slightly to $66m
Our rNPV-based valuation has increased to $66m/52c per share (NIS244m or NIS1.92/share) from $61m/48c/share, following the FY16 results and rolling our model forward by one quarter. Our 2017 and 2018 forecasts remain broadly similar and we continue to forecast a funding requirement this year. We have modelled illustrative long-term debt of NIS16m in 2017, which on our current forecasts would give CollPlant a cash horizon to early 2019. The company has a strong track record of raising capital in Israel and we expect upside potential as it progresses the application of its rhCollagen. Other potential catalysts include finding a partner or raising additional funding to develop its bone void filler and/or additional applications of its technology such as BioInk for 3D printing of organs and sales traction in Europe.
Exhibit 1: Financial summary
NIS'000s |
2014 |
2015 |
2016 |
2017e |
2018e |
||
Year end 31 Dec |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|||||||
Revenue |
|
|
0 |
0 |
292 |
1,260.57 |
2,948.78 |
Cost of Sales |
0 |
0 |
0 |
(630) |
(1,474) |
||
Gross Profit |
0 |
0 |
292 |
630 |
1,474 |
||
R&D expenses, net |
(9,734) |
(11,864) |
(16,789) |
(13,431) |
(15,446) |
||
SG&A expenses |
(3,906) |
(6,950) |
(11,048) |
(3,535) |
(3,889) |
||
EBITDA |
|
|
(12,838) |
(18,026) |
(27,023) |
(15,535) |
(17,150) |
Operating Profit (before GW and except) |
|
(13,640) |
(18,814) |
(27,545) |
(16,336) |
(17,860) |
|
Intangible Amortisation |
0 |
0 |
0 |
0 |
0 |
||
Exceptionals |
0 |
0 |
0 |
0 |
0 |
||
Operating Profit |
(13,640) |
(18,814) |
(27,545) |
(16,336) |
(17,860) |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Net Interest |
617 |
164 |
(348) |
20 |
76 |
||
Profit Before Tax (norm) |
|
|
(13,023) |
(18,650) |
(27,893) |
(16,316) |
(17,785) |
Profit Before Tax (FRS 3) |
|
|
(13,023) |
(18,650) |
(27,893) |
(16,316) |
(17,785) |
Tax |
0 |
0 |
0 |
0 |
0 |
||
Profit After Tax (norm) |
(13,023) |
(18,650) |
(27,893) |
(16,316) |
(17,785) |
||
Profit After Tax (FRS 3) |
(13,023) |
(18,650) |
(27,893) |
(16,316) |
(17,785) |
||
Average Number of Shares Outstanding (m) |
80.4 |
84.7 |
100.6 |
128.3 |
128.3 |
||
EPS - normalised (NIS) |
|
|
(16.19) |
(22.03) |
(27.72) |
(12.72) |
(13.86) |
EPS - FRS 3 (NIS) |
|
|
(16.19) |
(22.03) |
(27.72) |
(12.72) |
(13.86) |
Dividend per share (NIS) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
4,348 |
4,971 |
6,364 |
5,907 |
5,782 |
Intangible Assets |
1,725 |
1,721 |
1,631 |
1,631 |
1,631 |
||
Tangible Assets |
2,007 |
2,612 |
4,008 |
3,551 |
3,426 |
||
Other |
616 |
638 |
725 |
725 |
725 |
||
Current Assets |
|
|
12,610 |
8,558 |
8,069 |
19,253 |
5,310 |
Stocks |
0 |
0 |
487 |
487 |
487 |
||
Debtors |
1,548 |
3,241 |
3,785 |
3,785 |
3,785 |
||
Cash |
11,062 |
5,317 |
3,797 |
14,981 |
1,038 |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Current Liabilities |
|
|
(2,647) |
(3,750) |
(6,806) |
(6,806) |
(6,806) |
Creditors |
(1,642) |
(2,496) |
(5,189) |
(5,189) |
(5,189) |
||
Short term borrowings |
0 |
0 |
0 |
0 |
0 |
||
Short term leases |
0 |
0 |
0 |
0 |
0 |
||
Other |
(1,005) |
(1,254) |
(1,617) |
(1,617) |
(1,617) |
||
Long Term Liabilities |
|
|
0 |
0 |
(2,467) |
(18,467) |
(18,467) |
Long term borrowings |
0 |
0 |
(286) |
(16,286) |
(16,286) |
||
Long term leases |
0 |
0 |
0 |
0 |
0 |
||
Other long term liabilities |
0 |
0 |
(2,181) |
(2,181) |
(2,181) |
||
Net Assets |
|
|
14,311 |
9,779 |
5,160 |
(113) |
(14,181) |
CASH FLOW |
|||||||
Operating Cash Flow |
|
|
(12,958) |
(14,496) |
(19,384) |
(11,852) |
(13,282) |
Net Interest |
(35) |
(2) |
8 |
(20) |
(76) |
||
Tax |
35 |
1 |
0 |
0 |
0 |
||
Capex |
(336) |
(1,389) |
(492) |
(344) |
(585) |
||
Acquisitions/disposals |
0 |
0 |
0 |
0 |
0 |
||
Financing |
0 |
10,010 |
18,505 |
7,400 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
0 |
||
Other |
(16) |
27 |
(286) |
0 |
0 |
||
Net Cash Flow |
(13,310) |
(5,849) |
(1,649) |
(4,816) |
(13,944) |
||
Opening net debt/(cash) |
|
|
(23,777) |
(11,062) |
(5,317) |
(3,511) |
1,305 |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
||
Other |
595 |
104 |
(157) |
0 |
0 |
||
Closing net debt/(cash) |
|
|
(11,062) |
(5,317) |
(3,511) |
1,305 |
15,248 |
Source: Edison Investment Research and Company accounts
|
|
Research: Investment Companies
The Brunner Investment Trust (BUT) is a well-established fund investing in a relatively concentrated portfolio of c 70 global equities, aiming to generate long-term growth in capital and income. Over time, the number of holdings has been reduced and the proportion invested in overseas equities has increased. Lucy Macdonald has been sole manager since June 2016, and now uses her bottom-up stock selection process to invest in both UK and overseas companies. BUT’s style balance between growth and value stocks meant that relative performance was maintained during a significant market style shift from growth to value stocks in Q416. BUT has increased its annual dividend in each of the last 45 consecutive years; its current yield of 2.3% compares favourably with its peer group.